Westwood Holdings Group Inc. Increases Holdings in Prestige Consumer Healthcare Inc. $PBH

Westwood Holdings Group Inc. increased its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 2.4% during the second quarter, according to its most recent filing with the SEC. The fund owned 881,908 shares of the company’s stock after buying an additional 20,626 shares during the quarter. Westwood Holdings Group Inc. owned 1.79% of Prestige Consumer Healthcare worth $70,420,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the stock. Public Sector Pension Investment Board raised its position in Prestige Consumer Healthcare by 6.2% in the second quarter. Public Sector Pension Investment Board now owns 189,134 shares of the company’s stock worth $15,102,000 after acquiring an additional 11,115 shares during the period. Tower Research Capital LLC TRC increased its stake in shares of Prestige Consumer Healthcare by 327.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,823 shares of the company’s stock worth $385,000 after purchasing an additional 3,694 shares during the last quarter. Corient Private Wealth LLC raised its holdings in shares of Prestige Consumer Healthcare by 3.9% in the 2nd quarter. Corient Private Wealth LLC now owns 20,394 shares of the company’s stock worth $1,628,000 after purchasing an additional 762 shares during the period. State of Tennessee Department of Treasury lifted its stake in Prestige Consumer Healthcare by 16.1% in the second quarter. State of Tennessee Department of Treasury now owns 14,188 shares of the company’s stock valued at $1,133,000 after purchasing an additional 1,970 shares during the last quarter. Finally, Vident Advisory LLC lifted its stake in Prestige Consumer Healthcare by 14.7% in the second quarter. Vident Advisory LLC now owns 4,859 shares of the company’s stock valued at $388,000 after purchasing an additional 623 shares during the last quarter. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on PBH. Oppenheimer decreased their target price on Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating for the company in a research report on Tuesday, October 21st. Sidoti raised Prestige Consumer Healthcare from a “neutral” rating to a “buy” rating and set a $80.00 price objective for the company in a report on Wednesday, September 24th. Weiss Ratings restated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research note on Wednesday, October 8th. Jefferies Financial Group cut their target price on shares of Prestige Consumer Healthcare from $75.00 to $71.00 and set a “hold” rating for the company in a research report on Monday, October 27th. Finally, Zacks Research upgraded shares of Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research note on Monday, November 10th. Four equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, Prestige Consumer Healthcare presently has a consensus rating of “Moderate Buy” and an average price target of $85.33.

Prestige Consumer Healthcare Stock Performance

Shares of PBH opened at $61.47 on Friday. Prestige Consumer Healthcare Inc. has a 52-week low of $57.25 and a 52-week high of $90.04. The stock’s 50-day simple moving average is $60.79 and its 200 day simple moving average is $68.89. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.51 and a current ratio of 3.70. The stock has a market capitalization of $2.96 billion, a price-to-earnings ratio of 15.25, a price-to-earnings-growth ratio of 1.93 and a beta of 0.39.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings results on Thursday, November 6th. The company reported $1.07 earnings per share for the quarter, beating the consensus estimate of $0.97 by $0.10. Prestige Consumer Healthcare had a return on equity of 12.43% and a net margin of 18.09%.The firm had revenue of $274.11 million for the quarter, compared to analysts’ expectations of $257.14 million. During the same period in the prior year, the business posted $1.09 earnings per share. The company’s revenue was down 3.4% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. Research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

Insiders Place Their Bets

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 719 shares of the stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $60.00, for a total value of $43,140.00. Following the sale, the vice president directly owned 42,329 shares in the company, valued at $2,539,740. This represents a 1.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 1.40% of the company’s stock.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.